Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice.
The objective of this study was to develop and evaluate squalane oil-containing water-in-oil-in-water (W/O/W) multiple emulsion for mucosal administration of ovalbumin (OVA) as a model candidate vaccine in BALB/c mice. Control and optimized OVA-containing W/O/W emulsion (OVA-Emul) and chitosan-modified W/O/W emulsion (OVA-Emul-Chi) formulations were administered intranasally and orally at an OVA dose of 100 mug. The mucosal and systemic immune responses were evaluated after the first and second immunization. The OVA-Emul formulations resulted in higher immunoglobulin-G (IgG) and immunoglobulin-A (IgA) responses as compared with aqueous solution. In addition, significant IgG and IgA responses were observed after the second immunization dose using the emulsions with both routes of administration. Intranasal vaccination was more effective in generating the systemic OVA-specific IgG response than the mucosal OVA-specific IgA response. Oral immunizations, on the other hand, showed a much higher systemic IgG and mucosal IgA responses as compared with the nasally treated groups. The results of this study show that squalane oil-containing W/O/W multiple emulsion formulations can significantly enhance the local and systemic immune responses, especially after oral administration, and may be adopted as a better alternative in mucosal delivery of prophylactic and therapeutic vaccines.
Shahiwala
Aliasgar
A
Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA.
Amiji
Mansoor M
MM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D048271:Chitosan; D004337:Drug Carriers; D004563:Electrochemistry; D004655:Emulsions; D005260:Female; D007109:Immunity / Q000187:drug effects*; D018928:Immunity, Mucosal / Q000187:drug effects*; D007074:Immunoglobulin G / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles; D009504:Neutrophils / Q000187:drug effects; D010047:Ovalbumin / Q000276:immunology; D010316:Particle Size; D013185:Squalene / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D013535:Suspensions; D014867:Water
D000276:Adjuvants, Immunologic; D004337:Drug Carriers; D004655:Emulsions; D007074:Immunoglobulin G; D013535:Suspensions; D014867:Water; D013185:Squalene; D010047:Ovalbumin; D048271:Chitosan; C019556:squalane